Q1 2025 Repligen Corp Earnings Call Transcript
Key Points
- Repligen Corp (RGEN) reported a strong start to 2025 with 11% organic revenue growth in Q1, and 14% organic non-COVID growth.
- The company experienced high growth in its Proteins franchise, outperforming expectations, and Chromatography and Analytics both grew double digits.
- Orders were up high teens year-on-year with all franchises growing double digits, indicating strong demand across the portfolio.
- Repligen Corp (RGEN) made strategic progress with the acquisition of 908 Devices' bioprocessing portfolio, enhancing its position in new modalities and process analytics technology.
- The company maintained a strong cash position of $697 million at the end of Q1 2025, providing financial flexibility for future investments and acquisitions.
- Repligen Corp (RGEN) faced challenges in the capital equipment segment, with revenues declining year-on-year due to timing issues.
- China's market performance was weak, representing only 2% of Q1 revenues and orders, highlighting regional challenges.
- The small biotech segment showed weakness, with sales to emerging markets declining by high single digits.
- The company is exposed to potential tariff impacts, particularly in Europe, which could affect revenue and margins if retaliatory duties are imposed.
- Biotech funding decreased significantly in Q1 2025, which could impact the future health of the ecosystem and Repligen Corp (RGEN)'s growth prospects.
Good day, ladies and gentlemen, and welcome to Repligen Corporation's first quarter of 2025 earnings conference call. My name is Dovin, and I will be your coordinator. (Operator Instructions) Please note that there will be a question-and-answer session following the company's formal remarks. The company would like to note that there will be a limited time frame for Q&A and as such, management kindly requests that each individual asks one question to try to accommodate all.
I would like to turn the call over to your host for today's call, Jacob Johnson, Vice President of Investor Relations for Repligen.
Thank you, operator. And welcome to our first quarter of 2025 report. On this call, we will cover business highlights and financial performance for the three-month period ending March 31, 2025, and we'll provide financial guidance for the full-year 2025. Joining us on the call today are Repligen's President and Chief Executive Officer, Olivier Loeillot; and our Chief Financial Officer,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
